These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35308180)

  • 1. Role of inflammation in diabetic cardiomyopathy.
    Ramesh P; Yeo JL; Brady EM; McCann GP
    Ther Adv Endocrinol Metab; 2022; 13():20420188221083530. PubMed ID: 35308180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.
    Frati G; Schirone L; Chimenti I; Yee D; Biondi-Zoccai G; Volpe M; Sciarretta S
    Cardiovasc Res; 2017 Mar; 113(4):378-388. PubMed ID: 28395009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape.
    Haye A; Ansari MA; Rahman SO; Shamsi Y; Ahmed D; Sharma M
    Eur J Pharmacol; 2020 Dec; 888():173376. PubMed ID: 32810493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
    Jia G; Hill MA; Sowers JR
    Circ Res; 2018 Feb; 122(4):624-638. PubMed ID: 29449364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.
    Rajesh M; Bátkai S; Kechrid M; Mukhopadhyay P; Lee WS; Horváth B; Holovac E; Cinar R; Liaudet L; Mackie K; Haskó G; Pacher P
    Diabetes; 2012 Mar; 61(3):716-27. PubMed ID: 22315315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.
    Stanton AM; Vaduganathan M; Chang LS; Turchin A; Januzzi JL; Aroda VR
    Curr Diab Rep; 2021 Sep; 21(10):41. PubMed ID: 34580767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic cardiomyopathy: prevalence, determinants and potential treatments.
    Gulsin GS; Athithan L; McCann GP
    Ther Adv Endocrinol Metab; 2019; 10():2042018819834869. PubMed ID: 30944723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways.
    Joubert M; Manrique A; Cariou B; Prieur X
    Diabetes Metab; 2019 Jun; 45(3):238-247. PubMed ID: 30078623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
    Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
    Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic cardiomyopathy--fact or fiction?
    Maisch B; Alter P; Pankuweit S
    Herz; 2011 Mar; 36(2):102-15. PubMed ID: 21424347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure in Type 2 Diabetes Mellitus.
    Kenny HC; Abel ED
    Circ Res; 2019 Jan; 124(1):121-141. PubMed ID: 30605420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice.
    Hsuan CF; Teng SIF; Hsu CN; Liao D; Chang AJ; Lee HL; Hee SW; Chang YC; Chuang LM
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-20a-5p overexpression prevented diabetic cardiomyopathy via inhibition of cardiomyocyte apoptosis, hypertrophy, fibrosis and JNK/NF-κB signalling pathway.
    Liu X; Guo B; Zhang W; Ma B; Li Y
    J Biochem; 2021 Oct; 170(3):349-362. PubMed ID: 33837411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats.
    Yu W; Wu J; Cai F; Xiang J; Zha W; Fan D; Guo S; Ming Z; Liu C
    PLoS One; 2012; 7(12):e52013. PubMed ID: 23251674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control.
    Borghetti G; von Lewinski D; Eaton DM; Sourij H; Houser SR; Wallner M
    Front Physiol; 2018; 9():1514. PubMed ID: 30425649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.
    Huynh K; Bernardo BC; McMullen JR; Ritchie RH
    Pharmacol Ther; 2014 Jun; 142(3):375-415. PubMed ID: 24462787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diabetic cardiomyopathy.
    Tarquini R; Lazzeri C; Pala L; Rotella CM; Gensini GF
    Acta Diabetol; 2011 Sep; 48(3):173-81. PubMed ID: 20198391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Senescence and Type 2 Diabetic Cardiomyopathy: How Young Can You Die of Old Age?
    Henson SM; Aksentijevic D
    Front Pharmacol; 2021; 12():716517. PubMed ID: 34690759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.
    Evangelista I; Nuti R; Picchioni T; Dotta F; Palazzuoli A
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Animal Models in Diabetic Cardiomyopathy.
    Lee WS; Kim J
    Diabetes Metab J; 2021 Mar; 45(2):129-145. PubMed ID: 33813812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.